Metabolic and hormonal assessment of adolescent and young adult women with prior premature adrenarche by Ribeiro, Flávia Alves et al.
Metabolic and hormonal assessment of adolescent and
young adult women with prior premature adrenarche
Fla´via Alves Ribeiro0000-0001-9821-5074 , Elisabete Aparecida Mantovani Rodrigues de Resende0000-0003-0618-1968 , Adriana Paula da Silva0000-0001-5275-9981 ,
Janaı´ne Machado Tome´0000-0002-2395-6895 , Heloı´sa Marcelina da Cunha Palhares0000-0002-8153-8827 , Maria de Fa´tima Borges0000-0002-2294-848X *
Divisao de Endocrinologia e Metabolismo, Universidade Federal do Triangulo Mineiro (UFTM), Uberaba, MG, BR.
Ribeiro FA, Resende EA, Silva AP, Tome´ JM, Palhares HM, Borges MF. Metabolic and hormonal assessment of adolescent and young adult women with prior
premature adrenarche. Clinics. 2019;74:e836
*Corresponding author. E-mail: borgmf@uol.com.br
OBJECTIVE: Follow-up studies of girls with premature adrenarche have reported the development of polycystic
ovary syndrome, insulin resistance, and dyslipidemia and a propensity to cardiovascular disease. The aim of this
study was to analyze the presence of these conditions in patients previously treated at the Universidade Federal
do Triaˆngulo Mineiro.
METHODS: A total of 130 medical records reported premature adrenarche. One hundred and twenty-two
patients were invited to participate, of whom 54 accepted; 34 patients were selected, as they had reached their
final height. Anthropometric, blood glucose, insulin, and lipid and hormonal profile (LH, FSH, estradiol, 17a-OH-
progesterone, androstenedione, dehydroepiandrosterone sulfate, testosterone) data were obtained, the
HOMA-IR index was calculated, and pelvic ultrasonography was performed. To characterize polycystic ovary
syndrome and metabolic syndrome, the Rotterdam and International Diabetes Federation criteria, respectively,
were used. Data were analyzed according to measures of dispersion, frequency and correlations of interest.
RESULTS: The age of the participants ranged from 15.2 to 28.2 years/months; 23.5% of the patients were
overweight, 11.8% were obese, 29.4% had a large waist circumference, and 8.8% were hypertensive. None
of the patients had altered glucose levels, and insulin levels and HOMA-IR were elevated in 29.4% and 38.2%
of the participants, respectively; 14.7% of the patients exhibited acanthosis nigricans. The lipid profiles of the
participants were variable, and one patient (2.9%) had metabolic syndrome. Polycystic ovary syndrome was
found in 41.2% of patients.
CONCLUSION: The percentage of patients with polycystic ovary syndrome who also had overweight, obesity and
insulin resistance corroborates the literature data about the need for follow-up aiming at interventions,
especially for conditions associated with cardiometabolic risk.
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’ INTRODUCTION
Some children develop isolated and idiopathic premature
adrenarche (PA), which is defined as the onset of androgenic
signs before 8 years of age in girls and 9 years of age in boys,
in the absence of true puberty, steroidogenic enzymatic
defects and virilizing tumors. PA corresponds to the presence
of androgen action signs, including adult body odor, oily
skin and pubic hair growth. Precocious pubarche (PP) more
specifically refers to the early appearance of pubic and/or
axillary hair in these age groups (1,2).
The incidence of PA varies among different ethnic popu-
lations, with reports of incidence rates varying from 5% to
30% and a higher incidence in non-Hispanic black and white
children; PA has been reported to be up to 10 times more
common in girls than in boys (3,4).
The etiology of PA is not well understood. It is postulated
that its onset arises as a result of the early activation of the
maturation of the adrenal reticular zone, which is associated
with increased production of adrenal androgens, and as a
result of increased peripheral conversion of adrenal andro-
gens to testosterone and dihydrotestosterone (1,2).
The diagnosis of PA requires the exclusion of other causes
of excess androgens, such as congenital adrenal hyperplasia,
androgen-producing tumors, precocious puberty or exogen-
ous sources of androgens. In general, obtaining a thorough
history and performing a physical examination and baseline
measurement of adrenal androgens and eventually gonado-
tropins is sufficient to make a differential diagnosis between
idiopathic PA and these conditions (1,2,5).
Until the late 1990s, PAwas considered a benign variant of
pubertal development, with no need for special monitoring.
Subsequently, several studies have correlated PA with
metabolic syndrome (MS) components and with several
other disorders, including functional adrenal hyperandro-
genism (5,6).DOI: 10.6061/clinics/2019/e836
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Ibáñez et al., in follow-up studies of 35 teenage girls with
PA, reported a spectrum of endocrine-metabolic abnormal-
ities in 16 girls (45%); these abnormalities included central
adiposity, even in the absence of obesity; hirsutism; men-
strual disorders; and polycystic ovary syndrome (PCOS).
Furthermore, hyperinsulinemia, insulin resistance, increased
levels of androgens associated with patterns of ovarian and
adrenal hyperresponsiveness, and adrenocorticotropic hor-
mone (ACTH) and gonadotropin-releasing hormone (GnRH)
agonist stimulation were found. In addition, a shift in the
activity of adrenal enzymes was observed, with the accretion
of 17,20-lyase and 17-hydroxylase activities, resulting in
elevated levels of DHEA and DHEA sulfate (DHEA-S) for
chronological age (5,7).
Miller (9) suggested a ‘‘unified theory of adrenarche, PCOS
and hyperinsulinemia’’, and Ibáñez et al. (4) suggested that
the underlying mechanism may be abnormal regulation or
increased expression of the CYP17A1 androgen synthesis
enzyme in the adrenals and ovaries (5). The researchers
suggested precocious treatment with metformin, an insulin-
sensitizing drug, and lifestyle changes aimed at reducing
hyperinsulinemia, as some authors have suggested as a
treatment for PCOS (10-13).
In view of the literature reports, and considering that PA
predisposes patients to hormonal abnormalities, an increased
probability of developing PCOS, and conditions related to
cardiometabolic risk, we intend to assess if such abnormal-
ities are present in our environment and in patients who
were previously treated and followed up at the Endocrino-
logy Outpatient clinic for PA.
’ METHODS
Data collection occurred between March and December
2016, after the project was approved by the Human Research
Ethics Committee of Universidade Federal do Triângulo
Mineiro. Data were collected while patients were being
treated at the Gonads and Adrenal Outpatient Clinic of the
Discipline of Endocrinology and Metabology, after signing
the free and informed consent form.
A total of 130 medical records were obtained from the files
of patients with a diagnosis of PA. After analysis, eight
patients were excluded because they had central precocious
puberty. One hundred and twenty-two patients were invited
by letter for re-evaluation, and only 54 accepted the invita-
tion. After the initial consultation, 20 patients who had not
yet reached menarche or had not reached their final height
were excluded; thus, a total of 34 patients were selected for
study inclusion.
Anamnesis and a physical examination were performed as
well as an anthropometric evaluation that included weight,
height, body mass index (BMI), abdominal circumference
(AC), blood pressure (BP), pubertal staging, the presence
of acne and acanthosis nigricans, and body hair distribution
to identify hirsutism according to the Ferriman-Gallwey
score (14).
Weight was measured using a digital scale (Filizolas, São
Paulo, Brazil) with a capacity of up to 300 kg. Height was
measured using a wall stadiometer (Tonelis, Criciúma, Brazil,
model E 150 A) while the participant was in the standing
position, barefoot, with feet placed together. BMI was
calculated by dividing the weight by the height squared.
The BMI Z-score (Z-BMI) was used to classify the nutri-
tional status of those younger than 19 years, and the Z-BMI
was standardized according to the World Health Orga-
nization (WHO) criteria (15) and was calculated with
WHO-Anthro Plus 2007 (Geneva, Switzerland). The WHO
classification was also used for patients older than 19 years.
The AC was measured using an inextensible measuring tape
graduated in millimeters at the midpoint between the lower
border of the last rib and the upper border of the iliac crest
with the patient in the standing position. For girls up to
17 years old, the AC was considered to be high when its
value wasX the 90th percentile (16). For women older than
17 years, the AC was considered to be high when its value
was X80 cm, according to the International Diabetes Federa-
tion (IDF) consensus (17).
The homeostatic model assessment for insulin resistance
(HOMA-IR) index was calculated according to the formula:
Fasting glucose (mmol/L) x Fasting insulin (mU/mL)/22.5
(18). The reference for the HOMA-IR index for the Brazilian
population, according to the BRAMS study for individuals
X18 years is as follows: normalo2.7 and elevatedX2.7 (19).
According to the Brazilian Diabetes Society in its 2015-
2016 guidelines and based on a study by Stern et al. (20), the
presence of insulin resistance should be evaluated based on
three parameters: 1) BMI 428.9 kg/m2, 2) HOMA-IR 44.6
and 3) BMI 427.5 kg/m2 associated with HOMA-IR 43.6,
and for those younger than 18 years of age, the HOMA-IR
cut-off value of 3.43 is considered for Tanner 4 and 5
adolescents (21).
The presence of acanthosis nigricans was verified through
visual assessment of the skin in regions such as the neck,
armpits, and inguinal region; the presence of acne was also
verified through visual assessment of the skin. Hirsutism
was assessed using the Ferriman-Gallwey score (14). BP was
measured using a stethoscope and sphygmomanometer on
the right arm, with the patient in the sitting position. BP
assessment was carried out according to the 7th Brazilian
Guideline of Systemic Arterial Hypertension (22). Pubertal
staging was evaluated visually and classified according to
the Marshal and Tanner criteria (23).
The following laboratory tests were performed after a 10-
12 hour fasting period: fasting glucose (FG), basal insulin
(BI), glycated hemoglobin (HbA1c), total cholesterol (TC),
triglycerides (TGs), HDL-cholesterol (HDL-c), LDL-cholesterol
(HDL-c), non-HDL-cholesterol (NHDL-c), VLDL-cholesterol
(VLDL-c), luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), estradiol, thyroid-stimulating hormone (TSH),
free thyroxine (free T4), total testosterone, 17a-OH-progester-
one (17-OH-P), androstenedione (D4-A), and dehydroepian-
drosterone sulfate (DHEAS). The fasting glucose/insulin (FG/I)
ratio, the HOMA-IR index, and the triglyceride/HDL ratio
(TG/HDL) were also calculated.
FG and HbA1c were measured using the automated
colorimetric method, whereas TC, its fractions and TGs were
measured using the esterase cholesterol colorimetric enzy-
matic method. The lipid profile evaluation was performed
according to the V Brazilian Guideline on Dyslipidemias
and Atherosclerosis Prevention (24). The FG/I ratio was
considered altered when it was 40.30 (25). The TG/HDL
ratio was considered altered when it was 43.5 (26). HbA1c
values between 5.7 and 6.4% indicated individuals at high
risk for the development of diabetes, and levels X6.5
indicated the presence of diabetes (27).
To characterize MS in patients in the age range of 10-
17 years, the IDF criteria with adapted blood pressure levels
were used, considering an ACX90th percentile associated with
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two other criteria: FG X100 mg/dL or DM, TGs X150 mg/
dL, HDL-c o40 mg/dL, or systolic or diastolic BP X95th
percentile according to gender, age and height (17).
To characterize MS in adult women, the IDF criteria
were used, with ACX80 cm associated with two variables:
TGs X150 mg/dL or triglyceride-lowering treatment,
HDL-c o50 mg/dL, systolic BP X130 mmHg or diastolic
BP X85 mmHg or hypertension treatment, or FG X100 mg/
dL or DM2 (17).
LH, FSH, DHEAS, testosterone, insulin, TSH, and free T4
levels were measured using Elecsys Assay commercial kits
(Roche Diagnostics GmbH, Mannheim, Germany) according
to the electrochemiluminescence method (ECLIA) and were
analyzed in a Cobas 6000 and 601 automated system (Roche
Diagnostics). The minimum detection value was 0.1 mUI/mL
for both LH and FSH. The inter- and intra-assay coefficients
of variation (CVs) of LH are both approximately 2%. FSH has
inter- and intra-assay CVs of up to 4.5% and 2.8%, respec-
tively. The minimum detection values for DHEAS, testoster-
one, insulin, TSH, and free T4 were 0.1 mg/dL (interassay CV:
3.6% and intra-assay: 2.8%), 2.5 ng/mL (interassay CV: 8.4%
and intra-assay: 4.7%), 0.2 mU/mL (interassay CV: 2.6% and
intra-assay: 1.9%), 0.000014 mUI/L (interassay CV: 7.2%
and intra-assay: 3.0%) and 0.04 ng/dL (interassay CV: 6.3%
and intra-assay: 5.0%), respectively. Estradiol was also mea-
sured using the Elecsys Estradiol III Assay (Roche Diagnostics
GmbH, Mannheim, Germany) according to the ECLIA and
was analyzed by the same automated system as was used for
the abovementioned hormones. The method’s lower limit
value is 5 pg/mL, and the inter and intra-assay CVs were up to
10.6% and 6.7%, respectively.
The measurement of 17-OH-P was performed by radio-
immunoassay using NEXGENs equipment (Seoul, South
Korea), and the minimum detection value of the method was
0.052 ng/L, with inter- and intra-assay CVs up to 23.0% and
11.8%, respectively. Androstenedione was measured by che-
miluminescence with SIEMENS IMMULITE 2000s equip-
ment (Germany); the minimum detection value of the method
is 0.3 ng/mL, with inter- and intra-assay CVs up to 13.5% and
11.6%, respectively.
For the diagnosis of PCOS in adolescents, the presence of
three criteria was considered: clinical and biochemical
hyperandrogenism, oligoanovulation and enlarged or micro-
polycystic ovaries identified by an ultrasound assessment;
and irregular menstrual cycles that persisted for at least
2 years after menarche (28). In adult women, two diagnostic
consensuses were used, including the Rotterdam consensus
(29), which diagnoses PCOS when the patient has two of the
following three criteria: clinical and biochemical hyperan-
drogenism, oligoanovulation/anovulation and polycystic
ovaries identified by an ultrasound assessment. Polycystic
ovaries are considered based on the presence of at least 12
follicles measuring 2 to 9 mm and ovarian volume 410 mL.
the other consensus that was used was the Androgen Excess
Society (AES) Consensus (30), which requires clinical and
biochemical hyperandrogenism and ovarian dysfunction and/
or polycystic ovaries identified by an ultrasound assessment.
The latter includes a new technology that increased the
threshold of the ovarian follicle count to 25 from 2 to 9 mm
or ovarian volume 410 mL.
This is a descriptive study, and the variables of interest
were expressed through central and dispersion measures.
The Shapiro-Wilks test was used to verify the normal
distribution of the variables. Correlations between numerical
variables were analyzed by Pearson’s or Spearman’s tests,
depending on parametric or nonparametric distribution,
respectively; a p valuep0.05 was considered significant. The
calculations were performed using the IBM software SPSS,
STATISTIC version 20 (New York, USA).
’ RESULTS
Initial data of patients with premature adrenarche
The retrospective analysis of the selected patients’ files
showed that at the first consultation, the patients ranged
from 10 months to 10 years and seven months of age (median
7; 1). The mean weight Z-score was 0.3±1.7, and the mean
height Z-score was 0.3±1.3. The mean (Z-BMI) was 0.5±1.4.
Twenty-three patients had normal weight, five were over-
weight and six were obese.
The pubertal stage was B1P2 in 31 girls and B1P3 in three
girls. None of the girls had arterial hypertension. The FG
level was 85.4±12.3 mg/dL, and only three participants had
alterations in FG, but none of the participants had diabetes.
Regarding the lipid profile, the mean TC levels ranged from
111.5 to 254.2 (median: 142.0) and were elevated in six
patients. The mean TG levels were 100.4±44.8 mg/dL; the
TG levels were borderline in six patients and elevated in
three patients. The mean serum levels of HDL-c were
52.4±16.0 mg/dL and were low in four participants. The
mean serum LDL-c levels were 86.5±26.2 mg/dL and were
borderline in two patients and elevated in one patient.
Previous hormonal data showed TSH concentrations of
2.2±1.2 mIU/L. Only one patient showed subclinical hypo-
thyroidism. The mean estradiol level was 24.0±10.7 pg/mL.
The median LH level was 0.6 mIU/mL (minimum: 0.1,
maximum: 3.0), and the mean FSH concentration was
1.2±0.9 mIU/mL. The median testosterone level was 20.0
ng/dL (minimum: 1.0, maximum: 67.3), and three patients
had elevated testosterone levels. The median concentration
of DHEAS was 30.0 mg/dL (minimum: 2.0, maximum: 135.0),
and one patient had elevated DHEAS. The mean serum level
of 17-OH-P was 1.1±0.6 ng/mL; two patients had levels
42.0 ng/dL and were submitted to the ACTH analog test
(Cortrosyn, 250 mg iv), showing normal values. The average
birth weight was 2940.3±574.2 grams; the birth weight was
less than 2400 grams in six patients, of which three were
considered small for gestational age (SGA).
Current data
In the 34 patients selected, the median age was 20 years
and 3 months (minimum: 15.2; maximum: 28.2). The mean
weight was 63.8±14.5 kg, and the mean height was
162.8±7.3 cm. The mean BMI was 24.0±4.9 kg/m2. One
patient (2.9%) had low weight, 21 (61.8%) had normal
weight, eight (23.5%) were overweight and four (11.8%) were
obese.
The mean AC was 76.0±10.6 cm, and ten patients
(29.4%) had a large AC. The mean systolic BP (SBP) was
112.5±12.3 mmHg, and the mean diastolic BP (DBP) was
73.2±9.0 mmHg; three patients (8.8%) were categorized as
hypertensive. The Ferriman-Gallwey score was assessed in
20 patients, and 11 (55%) showed hirsutism (scoreX8). Acne
occurred in 13 patients (38.2%), and acanthosis nigricans
occurred in five (14.7%). Patients reported menarche at an
average age of 11 years and 10 months (minimum: 10.0,
maximum: 14.0). The clinical and anthropometric data are
shown in Table 1.
3
CLINICS 2019;74:e836 Assessment of prior premature adrenarche patients
Ribeiro FA et al.
Metabolic data are shown in Table 2. The mean FG was
79.7±9.4 mg/dL, and none of the patients had alterations.
The median HbA1c was 6.0% (minimum: 4.3%, maximum:
6.1%), and two patients (5.9%) had HbA1c values indi-
cative of glucose intolerance. The mean BI levels were
12.6±5.6 mIU/mL. Hyperinsulinemia was observed in ten
patients (29.4%). The mean insulin/FG (I/FG) ratio was 0.2
±0.1, and it was considered altered in two patients (5.9%).
The mean HOMA-IR index was 2.4±1.2. Of the patients
older than 18 years, eight (39.0%) had insulin resistance
according to Geloneze et al. (19), while six (28.6%) met the
criteria of Stern et al. (20). For those younger than eighteen
years, using the criteria of Gárcia-Cuartero et al. (21), five
patients (38.5%) had an increased HOMA-IR index.
The mean TC level was 168.9±24.8 mg/dL, and TC was
considered elevated in five patients (14.7%). The mean TG
concentration was 85.6±28.7 mg/dL and was elevated
in two patients (5.9%). The mean HDL-c concentration was
58.3±14.9 mg/dL, and five patients had low HDL-c levels.
The mean LDL-c level was 93.1±24.3 mg/dL, and the LDL-c
level was normal in all patients. The mean level of NHDL-c
was 110.6±26.6 mg/dL and was considered high in only one
Table 2 - Current metabolic data of the 34 patients assessed.
Assessed Parameters x±SD or Median# Minimum Maximum
FG (mg/dL) 79.7±9.4 57.9 93.3
HbA1c (%) 6.0 4.3 6.1
BI (mUI/mL) 12.6±5.6 2.0 25.8
I/FG ratio 0.2±0.1 0.03 0.4
HOMA-IR 2.4±1.2 0.02 4.7
TC (mg/dL) 168.9±24.8 121.6 226.4
TGs (mg/dL) 85.6±28.7 33.0 143.0
HDL-c (mg/dL) 58.3±14.9 30.0 92.0
LDL-c (mg/dL) 93.1±24.3 39.2 144.2
Non-HDL-c (mg/dL) 110.6±26.6 60.6 164.4
VLDL-c (mg/dL) 18.0±5.7 6.6 28.6
TG/HDL ratio 1.6±1.0 0.4 4.8
Source: the author, 2017.
#: according to normal or nonnormal distribution
FG (Fasting glucose): normal o100; altered X100, diabetes X126 mg / dL
BI (basal insulin): normal o15; altered X15
FG/I: fasting glucose/insulin ratio
HbA1c (glycated hemoglobin): normal o5.7; 5.7-6.4 = increased risk for diabetes, X6.5, diabetes
HOMA - IR: adults 418 years = normal until 2.7; adolescents Tanner IV and V = up to 3.43
TC (total cholesterol) 420 years: desirable o200; borderline: 200-239; high 4240
TC (total cholesterol) 2-19 years: desirable o150; borderline: 150-169; high X170
TGs (triglycerides) 420 years: desirable o150; borderline: 150-200; high: 200-499; very high X500
TGs (triglycerides) 2-19 years: desirable o100; borderline: 100-129; high X130
HDL-c (HDL-cholesterol) 420 years: desirable 460; low o40
HDL-c (HDL-cholesterol) 2-19 years: X45
LDL-c (LDL-cholesterol) 420 years: optimal o100; desirable: 100-129; borderline: 130-159; high: 160-189; very high X190
LDL-c (LDL-cholesterol) 2-19 years: desirable o100; borderline: 100-129; high X130
Non-HDL-c (non-HDL-cholesterol) 420 years: optimal o130; desirable: 130-159; high: 160-189; very High X190
VLDL-c (VLDL-cholesterol) 420 years: desirable o30; High 430
TG/HDL (triglyceride/HDL-cholesterol ratio): altered 43.5
FG/I (fasting glucose/insulin ratio) 40.30 altered
Table 1 - Current clinical and anthropometric data of the 34 patients assessed.
Assessed Parameters x±SD or Median# Minimum Maximum
Age (years; months) 20.3 15.2 28.2
Weight (kg) 63.8±14.5 42.5 105.9
Height (cm) 162.8±7.3 151.0 179.0
BMI (kg/m2) 24.0±4.9 16.5 36.6
AC (cm) 76.0±10.6 60.0 106.5
SBP (mmHg) 112.5±12.3 90.0 150.0
DBP (mmHg) 73.2±9.0 60.0 90.0
Ferriman-Gallwey score (n=20) 9.0±5.7 1 20
Menarche (years; months) 11.1 10.0 14.0
Source: The author, 2017.
#: according to normal or normal distribution
BMI (body mass index): 419 years: low weight o18; normal weight: 18-24.9; overweight: 25-29.9; obesity 430. BMI (kg/m2) o19 years; normal weight
-2p z-BMI o+1; overweight +1 p z-BMI o+2; obesity z-BMI X+2
AC (abdominal circumference) 417 years: normal o80; altered 480; AC o17 years: high X90th percentile
SBP (systolic blood pressure) and DBP (diastolic blood pressure) p17 years of age: hypertensive X95th percentile
SBP (systolic blood pressure) 417 years: Normal p120; Prehypertension: 121-139; Hypertension X140. DBP (diastolic blood pressure) 417 years: normal
p80; prehypertension: 81-89; hypertension X90
Ferriman-Gallwey score: o8 normal; 48 hirsutism
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patient (2.9%). The mean TG/HDL ratio was 1.6±1.0, and
three patients (8.8%) had an increased ratio (26). Only one
patient (2.9%), aged 18 years and 3 months, met the criteria
for MS.
The hormonal data are shown in Table 3. The mean TSH
levels were 2.6±1.5 mIU/L. The TSH level was low in
two patients (5.9%), normal in 29 (85.3%), and elevated in
3 (8.8%). The mean level of free T4 was 1.2±0.2 ng/dL.
Four patients (11.8%) had low free T4 levels, and one (8.8%)
had a discreetly increased free T4 level.
It was proposed that blood samples for hormonal
assessment should be collected in the early follicular phase;
however, three patients (8.8%) did not meet our request. The
mean LH level was 6.0±4.2 mIU/mL, and the mean FSH
level was 4.4±1.9 mIU/mL. The mean LH/FSH ratio was
1.3±0.8, and it was X2 in nine patients (26.5%).
The mean testosterone levels were 29.6±14.0 ng/dL and
were increased in four patients (11.8%) and normal in 88.2%.
The mean DHEAS level was 193.3±99.9 mg/dL and was
analyzed according to age: in the patients younger than
19 years, the DHEAS levels were normal in 14 (87.5%) and
elevated in two (12.5%); among those aged 20 to 24 years,
the levels were normal in all cases, and in those aged 25 to
34 years, the levels were normal in six patients (85.7%) and
elevated in one patient (14.3%).
The mean level of 17-OH-P was 1.6±2.0 ng/mL. Eight
patients (23.5%) had elevated levels. These patients
were submitted to the ACTH analog test (Cortrosyn,
250 mg iv), and the resulting values ruled out adrenal
hyperplasia (1). The median D4-A levels were 2.1 ng/mL
(minimum: 0.3 ng/mL, maximum: 4.2 ng/mL), and two
patients (5.9%) had high levels.
The median volume of the right ovary was 7.2 mL
(minimum: 1.2 mL, maximum: 150.0 mL), and 12 patients
(35.3%) showed an increased volume. The median left ovary
volume was 7.5 mL (minimum: 1.5 mL, maximum: 96.0 mL),
and eight (23.5%) showed an increased volume. Eight
patients (23.5%) had ovaries with a micropolycystic aspects.
Among patients younger than 19 years, three (18.7%) met
the criteria for PCOS. Among patients older than 19 years,
eleven patients (62.0%) had PCOS according to the Rotter-
dam consensus criteria. Using the AES Consensus criteria,
the same eleven patients (62.0%) had PCOS, showing there
was a concordance between the two consensuses used. Overall,
14 patients (41.2%) met the criteria for PCOS.
Correlations between clinical and metabolic data were
analyzed: BMI showed a positive and weak correlation with
the insulin/glucose ratio (r=0.362, po0.05) and with the
HOMA-IR index (r=0.358, po0.05). The AC showed a
positive and moderate correlation with BI (r=0.526, po0.01)
and a weak correlation with HbA1c (r=0.352, po0.05), trigly-
cerides (r=0.544, po0.01), the insulin / glucose ratio (r=0.471,
po0.01), and HOMA-IR (r=0.613, po0.01). SBP presented a
moderate positive correlation with HbA1c (r=0.457, po0.01)
and a weak positive correlation with the HOMA-IR index
(r=0.338, po0.05). No significant correlations were observed
between the reported clinical and hormonal data.
There was a positive and weak correlation between birth
weight and the current metabolic data with the HOMA-IR
index (r=0.395, po0.05). Among patients for whom it was
possible to calculate target height (n=18), only four did not
reach it. The correlation between target height and final
height was positive and moderate (r=0.588; p=0.001). The
current BMI showed a correlation with the initial BMI
(r=0.713, p=0.001) and with the Z-score of the initial BMI
(r=0.550, po0.001). Correlations were observed between
current and initial 17-OH-P levels (r=0.496, po0.05).
’ DISCUSSION
The present study suggests, as previously reported in the
literature (5,6), that PA is not a ‘‘variant of normal’’ condition,
as it has been classically considered, and careful attention
should be directed to some aspects during the follow-up of
these children.
Despite the small percentage of MS in the patients (2.9%),
abnormalities related to cardiometabolic risk were present
as overweight (23.5%) and obesity (11.8%), and a significant
correlation was found between the current BMI and the
initial BMI (r=0.713, po0.01) and the initial (Z-BMI) (r=0.550,
Table 3 - Current hormonal data of the 34 patients assessed.
Assessed Parameters x±SD or Median# Minimum Maximum
TSH (mUI/L) 2.6±1.5 0.01 6.8
Free T4 (ng/dL) 1.2±0.2 0.7 1.7
LH (mUI/mL) 6.0±4.2 0.1 16.7
FSH (mUI/mL) 4.4±1.9 0.3 7.8
LH/FSH 1.3±0.8 0.3 3.0
E2 (pg/mL) 51.5 5.0 244.3
TESTOSTERONE (ng/dL) 29.6±14.0 9.0 68.7
DHEAS (mg/dL) 193.3±99.9 45.4 429.9
17a-OH-Progesterone (ng/mL) 1.6±2.0 0.2 5.7
D4-A (ng/mL) 2.1 0.3 4.2
Source: the author, 2017.
#: according to normal or nonnormal distribution
TSH (thyroid-stimulating hormone) normal: 0.27-4.20
Free T4 (free thyroxin) normal: 0.93-1.70
E2 (estradiol): follicular phase: 12.5-166; ovulatory phase: 85.8-498; luteal phase: 43.8-211
Testosterone, women: 20-49 years: 8.40-48.1
DHEAS (dehydroepiandrosterone sulfate): women 15-19 years: 65.1-368; 20-24 years: 148-407; 25-34 years: 98.8-340
17a-OH-progesterone (17 a hydroxyprogesterone) women: follicular phase: 0.11-1.08; luteal phase: 0.95-5.0
D4-A (androstenedione): women: 0.3-3.7
LH (luteinizing hormone): women: follicular phase: 2.4-12.6; ovulatory phase: 14.0-95.6; luteal phase: 1.0-11.4
FSH (follicle-stimulating hormone): women: follicular phase: 3.5-12.5; ovulatory phase: 4.7-21.5; luteal phase: 1.7-7.7
LH/FSH (luteinizing hormone/follicle-stimulating hormone ratio) o2.0 normal; 42.0 suggestive of PCOS
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po0.01). These data indicate the need for preventive mea-
sures against obesity in children with PA. According to the
Brazilian Guidelines for Obesity (30), an obese child will
remain obese in adulthood, and the likelihood ranges from
20-50% before puberty to 50-70% after puberty.
Systemic Arterial Hypertension (SAH) was observed in
8.8% of the patients, whereas the prevalence of SAH in Brazil
in individuals aged between 18 and 29 years is 2.8% and
ranges from 3 to 5% in the pediatric age range (31). BP shows
normal circadian fluctuations; adolescents with PCOS and
abnormal glucose tolerance have an interruption in these
fluctuations, and this may be a precursor for the develop-
ment of arterial hypertension in this population (32).
When analyzing the glucose metabolism data, only 5.88%
of the patients showed HbA1c levels indicative of glucose
intolerance, and FG was normal in all of the patients; how-
ever, as reported in the literature, several factors demon-
strated insulin resistance, such as acanthosis nigricans, which
occurred in 14.7% of the patients; fasting hyperinsulinemia,
which occurred in 29.4% of the patients; altered insulin/
glucose ratio, which occurred in 5.9% of the patients;
increased HOMA-IR index, which occurred in 38.2% of the
patients; and an altered TG/HDL ratio, which occurred in
8.8% of the patients, corroborating the findings of other
authors who associated PA with these conditions (1,2,4-6).
The lipid profile was adequate in most patients, but 14.7%
of the patients had high TC levels, and 5.88% had high
triglycerides, whereas 14.7% had low HDL-c levels. These are
young patients who already exhibit a lipid alteration pattern
associated with MS characterized by decreased HDL-c and
elevated triglyceride levels (33), suggesting the need for
patient guidance in relation to these aspects.
Positive and significant correlations between adiposity
indexes and insulin resistance markers are expected since
overweight/obese patients have insulin resistance; therefore,
a causal association between these variables is expected. The
same concept applies to the BP analysis, which showed a
moderate positive correlation with HbA1c (r=0.457, po0.01)
and with the HOMA-IR index (r=0.338, po0.05), suggesting
that HOMA-IR and HbA1c could be markers of cardiometa-
bolic risk.
According to Ibáñez et al. (4,5), children with intrauterine
growth retardation, or those who are SGA, are more likely to
show an increase in growth factors, such as IGF-1 and
hyperinsulinemia, as compensatory changes to catch up in
terms of weight and height, but as a consequence, they can
develop PA, insulin resistance, and MS during their life span.
The present study showed only three patients (8.8%) with
such conditions, and a significant positive correlation was
found between birth weight and the HOMA-IR index,
suggesting that being overweight at birth may also be
associated with the risk of obesity and insulin resistance
in adults.
Another group of abnormalities that was found was
related to androgenic action and gonadal function. Hirsutism
assessment using the Ferriman-Gallwey score showed limi-
tations because many patients had shaved before the
consultation, allowing the analysis in only 20 patients, and
the hirsutism status was altered in 55% of them. Hirsutism
affects 5 to 10% of women, and therefore, the percentages
found in the present study were higher than those in the
overall population (34). However, no statistically significant
correlation was found between the Ferriman-Gallwey score
and circulating androgen levels, corroborating the literature
data showing that hirsutism is associated with a localized
phenomenon of increased sensitivity of hair follicles to circu-
lating androgen levels, which are more intensely metabo-
lized at the receptor sites, which is one of the explanations of
PA pathophysiology and hirsutism (34).
When analyzing the hormonal data, an LH/FSH ratio
suggestive of PCOS (42) was found in 26.5% of the patients,
and androgen concentrations were in the normal range in the
majority of the patients (11.8% had high testosterone levels,
8.8% had elevated DHEAS levels). The most evident altera-
tion was observed in the 17-OH-P level, which was eleva-
ted in 23.5% of the patients. Although congenital adrenal
hyperplasia was ruled out, Ibanez et al. reported the
presence of functional ovarian and adrenal disorder in
patients with PA (4,7,8). Correlating the hormonal data
from the start of the follow-up with the current data, a
positive and significant correlation can be observed between
the initial levels of 17-OH-P (po0.05) and the current levels,
showing that this alteration was maintained during the
assessment period.
The presence of PCOS was found in 41.2% of the patients
in the sample studied, which is higher than the figure repor-
ted by March et al. (35), who found a prevalence of 6-10% in
a general population, and in the context of the abnormalities
observed, PCOS was described as being associated with
overweight/obesity, insulin resistance and MS. As sug-
gested, the pathophysiology of PCOS is complex, being the
common final pathway of a variety of metabolic and hor-
monal expressions, which occur in addition to the genetic
and epigenetic factors involved (29).
The present study has some limitations: a small number of
patients were analyzed; the 122 patients who were attended
at the Pediatric Endocrinology outpatient clinic should have
been followed up at the Gonads and Adrenal outpatient
clinic; however, surprisingly, they had to be called, and only
44.3% of the patients agreed to participate in the study. This
loss of follow-up limited the study to two cross-sections at
the beginning of the study period and at the present time; the
clinical hirsutism defined by the Ferriman-Gallwey score
could not be determined in all patients because they shaved
prior to the consultation. The strength of the study is the
demonstration that patients with PA should undergo long-
term follow-up aiming for the early intervention of cardio-
metabolic risk factors and SOP.
’ CONCLUSION
The percentage of individuals with PCOS in the patients
with PA was greater than that in the overall population,
which demonstrates that patients with PA share some
pathophysiological elements with PCOS, such as hyperinsu-
linemia, insulin resistance, functional adrenal alterations,
and other elements that are still poorly defined within the
complex pathophysiology of both conditions. PA should
not be considered a ‘‘variant of normal’’ child development
but rather a clinical event that deserves attention and early
intervention in terms of metabolic risk factors, PCOS and MS
during a long-term and careful follow-up.
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